DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20221044

A role of biomarkers in systemic lupus erythematous: a comprehensive review

Shashank Jindam, Pranav Koraseeka, Suvarna Addagarla, Ramya B. P. Gelly

Abstract


Systemic lupus erythematous (SLE) is an auto immune disease that can involve almost all body organs. Lupus erythematous may be classified in to several subtypes according to clinical features including systemic and cutaneous lupus erythematous, drug induced lupus and neonatal lupus. SLE progression includes in the immune system. Pathological manifestation of SLE are due to antibody formation and deposition of immune complexes in different organs of the body. Due to formation or disposition of immune complex in different body tissues and vessels, which may lead to complement activation and more organ damage. Other factors include genetic factors, hormonal abnormalities and environmental factors. There is a challenge in establishing a diagnosis, determining disease activity. Therefore, an important needs is a repertoire of biomarkers that can accurately with prediction, diagnosis, and disease, activity monitoring and stratifying patient. SLE can be diagnosed by using different biomarkers as anti-smith antibodies (ANAS), antibodies to double stand deoxyribonucleic acid (DNA) and level of complement components C3 C4, and CH50. More immunological biomarkers are needed to be better understanding of disease SLE. SLE is an autoimmune disease which can travel to any organ or a system i.e. biomarkers for cardiovascular involvement in SLE, biomarkers for respiratory involvement in SLE, biomarkers for lupus arthritis.


Keywords


Systemic lupus erythematous, Biomarkers, Diagnosis, Disease activity

Full Text:

PDF

References


Wasef SZ. Gender differences in systemic lupus erythematosus". Gender Med. 2004;1(1):12-7.

Ali A, Sayyed Z, Ameer MA, Arif AW, Kiran F, Iftikhar A, et al. Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management. Cureus. 2018;10(9):e3288.

Arodin SP, Jarjour WN. Biomarkers in systemic lupus erythematosus. Systemic Lupus Erythematosus. 2016;43-51.

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-89.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.

Emlen W, O’Neill L. Clinical significance of antinuclear antibodies: Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612-8.

Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13:538-47.

Li H, Lin S, Yang S, Chen L, Zheng X. Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus. Clin. Rheumatol. 2015;34:471-7.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65:2143-53.

Gómez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value. Autoimmune Rev. 2008;7:606-11.

Bertoli AM, Vila LM, Reveille JD, Alarcón GS. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol. 2008;35:2355-8.

Dima A, Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus. 2016;25:1173-9.

Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci. Med. 2018;5:e000263.

Kwon OC, Lee JS, Ghang B, Kim YG, Lee CK, Yoo B, Hong S. Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. Semin. Arthritis Rheum. 2018;48:462-6.

Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, Fabien N. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus. 2011;20:28-34.

Ceccarelli F, Perticone C, Colasanti T, Massarotti L. Anti Carbamylated protein antibodies as a new biomarker of erosive joint damage in Systemic lupus erythematous. Arthritis Research Therapy. 2018;20:126.

Kakumanu P, Sobel ES, Naranin S, Akaogi YL. Citrulline of anti cyclic citrullinated peptide antibodies in systemic lupus erythematous As a marker of deforming/erosive arthritis. J Rheumatol. 2009;36:12.

Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci. 2014;21:23.

López P, Rodríguez-Carrio J, Martínez-Zapico A, Pérez-Álvarez ÁI, Suárez-Díaz S, Mozo L, et al. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology. 2020;59:1752-64.

Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A. High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis Rheumatology. 2020;72:20-30.

Skeoch S, Haque S, Pemberton P, Bruce IN. Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus. 2014;23:819-24.